Randomised trial of azithromycin to eradicate Ureaplasma in preterm infants
JournalArchives of Disease in Childhood: Fetal and Neonatal Edition
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractObjective: To test whether azithromycin eradicates Ureaplasma from the respiratory tract in preterm infants. Design: Prospective, phase IIb randomised, double-blind, placebo-controlled trial. Setting: Seven level III-IV US, academic, neonatal intensive care units (NICUs). Patients: Infants 240-286 weeks' gestation (stratified 240-266; 270-286 weeks) randomly assigned within 4 days following birth from July 2013 to August 2016. Interventions: Intravenous azithromycin 20 mg/kg or an equal volume of D5W (placebo) every 24 hours for 3 days. Main outcome measures: The primary efficacy outcome was Ureaplasma-free survival. Secondary outcomes were all-cause mortality, Ureaplasma clearance, physiological bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age, comorbidities of prematurity and duration of respiratory support. Results: One hundred and twenty-one randomised participants (azithromycin: n=60; placebo: n=61) were included in the intent-to-treat analysis (mean gestational age 26.2±1.4 weeks). Forty-four of 121 participants (36%) were Ureaplasma positive (azithromycin: n=19; placebo: n=25). Ureaplasma-free survival was 55/60 (92% (95% CI 82% to 97%)) for azithromycin compared with 37/61 (61% (95% CI 48% to 73%)) for placebo. Mortality was similar comparing the two treatment groups (5/60 (8%) vs 6/61 (10%)). Azithromycin effectively eradicated Ureaplasma in all azithromycin-assigned colonised infants, but 21/25 (84%) Ureaplasma-colonised participants receiving placebo were culture positive at one or more follow-up timepoints. Most of the neonatal mortality and morbidity was concentrated in 21 infants with lower respiratory tract Ureaplasma colonisation. In a subgroup analysis, physiological BPD-free survival was 5/10 (50%) (95% CI 19% to 81%) among azithromycin-assigned infants with lower respiratory tract Ureaplasma colonisation versus 2/11 (18%) (95% CI 2% to 52%) in placebo-treated infants. Conclusion: A 3-day azithromycin regimen effectively eradicated respiratory tract Ureaplasma colonisation in this study. Copyright Author(s) 2020.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082194897&doi=10.1136%2farchdischild-2019-318122&partnerID=40&md5=ff4425b89d1d1e1667bf6a6ef8cfd621; http://hdl.handle.net/10713/12485
- Effect of antenatal azithromycin for Ureaplasma spp. on neonatal outcome at ≤30 weeks' gestational age.
- Authors: Kim SH, Chun J, Ko KH, Sung TJ
- Issue date: 2019 Jan
- Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.
- Authors: Merchan LM, Hassan HE, Terrin ML, Waites KB, Kaufman DA, Ambalavanan N, Donohue P, Dulkerian SJ, Schelonka R, Magder LS, Shukla S, Eddington ND, Viscardi RM
- Issue date: 2015 Jan
- Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial.
- Authors: Ballard HO, Shook LA, Bernard P, Anstead MI, Kuhn R, Whitehead V, Grider D, Crawford TN, Hayes D Jr
- Issue date: 2011 Feb
- Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose.
- Authors: Viscardi RM, Othman AA, Hassan HE, Eddington ND, Abebe E, Terrin ML, Kaufman DA, Waites KB
- Issue date: 2013 May
- Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.
- Authors: Hassan HE, Othman AA, Eddington ND, Duffy L, Xiao L, Waites KB, Kaufman DA, Fairchild KD, Terrin ML, Viscardi RM
- Issue date: 2011 Sep